Fort Duncan Medical Center LP
Fort Duncan Medical Center LP was paid $15.80M by Medicaid between Oct 2019 and Nov 2024, across 100 billing codes. Its largest line is 99284, emergency room visit (serious) — 44% of everything it billed.
EAGLE PASS, TX 78852
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 87 | $1K | |
| 2020 | 6,187 | $440K | |
| 2021 | 38,980 | $2.84M | |
| 2022 | 58,731 | $4.70M | |
| 2023 | 53,495 | $5.20M | |
| 2024incomplete | 27,178 | $2.62M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 44% | 11,632 | 11,259 | $6.88M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 23% | 6,721 | 6,240 | $3.71M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.1% | 5,610 | 5,473 | $1.11M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.7% | 2,388 | 2,267 | $592K |
| 71045 | Radiologic examination, chest; single view | 3.7% | 5,280 | 5,057 | $591K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.5% | 8,455 | 8,244 | $389K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 2.4% | 2,442 | 2,297 | $380K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.3% | 17,472 | 8,697 | $370K |
| 71046 | Radiologic examination, chest; 2 views | 2.3% | 2,987 | 2,917 | $365K |
| 87430 | 1.3% | 8,827 | 8,636 | $204K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.2% | 8,719 | 8,454 | $189K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,444 | 1,378 | $129K |
88 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,331 | $91K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 911 | $87K |
| 80053 | Comprehensive metabolic panel | <1% | 11,242 | $83K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 12,581 | $71K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,245 | $69K |
| 76801 | <1% | 435 | $67K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,218 | $63K |
| 87420 | <1% | 2,500 | $56K | |
| 71250 | <1% | 948 | $34K | |
| 59025 | Fetal non-stress test | <1% | 64 | $22K |
| 81001 | <1% | 7,621 | $17K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 225 | $16K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 65 | $16K |
| 83690 | <1% | 2,918 | $16K | |
| 84484 | <1% | 3,468 | $15K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 555 | $15K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 836 | $14K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,493 | $10K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 267 | $9K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,271 | $9K |
| 83874 | <1% | 2,607 | $8K | |
| 82550 | <1% | 2,747 | $7K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 140 | $6K |
| 83605 | <1% | 1,300 | $5K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 588 | $5K |
| 84703 | <1% | 467 | $5K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 87 | $5K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 759 | $4K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 60 | $3K |
| 87070 | <1% | 337 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,646 | $3K |
| 85610 | <1% | 1,797 | $3K | |
| 87040 | <1% | 1,290 | $3K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 44 | $3K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 13 | $3K |
| 82553 | <1% | 890 | $3K | |
| 83880 | <1% | 588 | $3K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 996 | $2K |
| 87186 | <1% | 1,149 | $2K | |
| 74018 | <1% | 14 | $2K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 685 | $2K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 732 | $2K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 55 | $2K |
| 81003 | <1% | 1,139 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 290 | $2K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 12 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 188 | $1K |
| 80061 | Lipid panel | <1% | 1,131 | $1K |
| 85730 | <1% | 859 | $1K | |
| 83735 | <1% | 1,067 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 958 | $1K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 16 | $1K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 286 | $686.70 |
| 84702 | <1% | 36 | $663.18 | |
| 82803 | <1% | 150 | $630.42 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 50 | $613.04 |
| 94664 | <1% | 17 | $546.05 | |
| 87077 | <1% | 355 | $519.23 | |
| 85027 | <1% | 212 | $504.79 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 791 | $495.85 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 83 | $438.34 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 454 | $436.06 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 454 | $378.36 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 132 | $366.67 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 910 | $248.26 |
| 84030 | <1% | 26 | $188.62 | |
| 72100 | <1% | 13 | $167.19 | |
| 36600 | <1% | 14 | $156.78 | |
| 80069 | <1% | 319 | $143.47 | |
| 73564 | <1% | 14 | $135.06 | |
| 87205 | <1% | 135 | $108.02 | |
| 82570 | <1% | 322 | $99.74 | |
| 86901 | <1% | 27 | $70.04 | |
| 86900 | <1% | 27 | $70.04 | |
| 84156 | <1% | 237 | $48.03 | |
| 82150 | <1% | 29 | $36.15 | |
| 84550 | <1% | 108 | $34.44 | |
| 82962 | <1% | 1,214 | $32.01 | |
| 83540 | <1% | 37 | $25.38 | |
| 84439 | <1% | 12 | $24.72 | |
| 83550 | <1% | 36 | $22.33 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 14 | $15.47 |
| A9270 | Non-covered item or service | 0% | 2,067 | $0.00 |
| 82607 | 0% | 44 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 19 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 148 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 17 | $0.00 |
| 36416 | 0% | 27 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| District Hospital Partners L P | Washington, DC | $136.25M |
| Mcallen Hospitals L P | Edinburg, TX | $124.61M |
| Lancaster Hospital Corporation | Palmdale, CA | $108.63M |
| Universal Health Services of Rancho Springs INC | Murrieta, CA | $61.95M |
| Doctors Hospital of Laredo | Laredo, TX | $52.31M |
| Valley Hospital Medical Center | Las Vegas, NV | $47.03M |
| Northwest Texas Healthcare System INC | Amarillo, TX | $44.81M |
| Uhs of Bowling Green LLC | Bowling Green, KY | $41.21M |
| Uhs-Corona INC | Corona, CA | $35.18M |
| Spring Valley Medical Center | Las Vegas, NV | $33.58M |
| Aiken Regional Medical Centers LLC | Aiken, SC | $31.51M |
| Summerlin Hospital Medical Center L L C | Las Vegas, NV | $30.26M |
| Manatee Memorial Hospital L P | Bradenton, FL | $22.33M |
| Desert Springs Hospital | Las Vegas, NV | $22.29M |
| Psi Pride Institute INC | Eden Prairie, MN | $15.57M |
| Uhs of Fuller INC | S Attleboro, MA | $13.47M |
| Uhs of Texoma, INC | Denison, TX | $12.51M |
| Arbour INC | Boston, MA | $12.36M |
| Wellington Regional Medical Center LLC | Wellington, FL | $10.75M |
| Friends Behavioral Health System, LP | Philadelphia, PA | $9.55M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.